Abstract
Systemic sclerosis is a challenging disease in terms of early risk assessment and the implications for therapy. The current article draws on a literature analysis and on personal experience of over 450 patients with systemic sclerosis and related illnesses, describing an attempt at a risk-adapted treatment strategy for patients with systemic sclerosis, and is intended to be used as a discussion paper. A major point of emphasis is on novel therapeutic options for patients who are refractory to current treatment strategies and who are at a high risk of serious complications or a limited prognosis. The paper also highlights possible future treatment options, including vasoactive, cellular and immune suppressant treatments.
| Translated title of the contribution | Clinical risk-adapted therapies in systemic sclerosis |
|---|---|
| Original language | German |
| Journal | Zeitschrift fur Rheumatologie |
| Volume | 66 |
| Issue number | 8 |
| Pages (from-to) | 672-678 |
| Number of pages | 7 |
| ISSN | 0340-1855 |
| DOIs | |
| Publication status | Published - 12.2007 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)
Fingerprint
Dive into the research topics of 'Clinical risk-adapted therapies in systemic sclerosis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver